What is ANRO stock price today?

ANRO (Alto Neuroscience Inc) stock is trading at $20.70 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ANRO stock going up or down today?

ANRO stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ANRO stock now?

The decision to buy ANRO depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ANRO a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ANRO based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ANRO stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ANRO is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ANRO's P/E ratio?

P/E ratio data for ANRO will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ANRO's market cap?

ANRO (Alto Neuroscience Inc) has a market capitalization of $0.64 billion, making it a small-cap stock.

What is ANRO's price to book ratio?

ANRO trades at a price-to-book (P/B) ratio of 5.78, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ANRO pay dividends?

ANRO does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ANRO's dividend yield?

ANRO does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ANRO stock a good long-term investment?

ANRO's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ANRO's revenue growth rate?

Revenue growth data for ANRO is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ANRO are available on our dashboard with complete income statement analysis.

What are the risks of investing in ANRO?

Key risks for ANRO include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ANRO compare to its competitors?

Compare ANRO to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ANRO's performance and positioning.

What is ANRO's stock price target for 2026?

Our AI model provides price targets for ANRO based on fundamental analysis: Bull case $26.92 (+30%), Base case $23.81 (+15%), Bear case $18.63 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ANRO?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ANRO. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ANRO's next earnings report?

ANRO reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ANRO - Alto Neuroscience Inc

NYSE * Health Care * Biotechnology

$20.70

+$0.13 (+0.61%)

About Alto Neuroscience Inc

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.

ANRO Key Statistics

Market Cap

$644.94M

P/B Ratio

5.78

EPS

$-2.30

Employees

How ANRO Compares to Peers

ANRO is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ANRO(This stock)	$644.94M	N/A	0%	0.0%	-
AMGNAmgen Inc	$199.20B	26.0	0%	0.2%	vs AMGN
GILDGilead Sciences	$178.68B	21.2	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$116.01B	29.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$80.33B	18.3	0%	0.3%	vs REGN
BIIBBiogen Inc	$27.13B	21.1	-0%	0.1%	vs BIIB

Alto Neuroscience Inc Company Information

Headquarters: California; U.S.A
Website: www.altoneuroscience.com
Sector: Health Care
Industry: Biotechnology

ANRO - Alto Neuroscience Inc

About Alto Neuroscience Inc

ANRO Key Statistics

How ANRO Compares to Peers

Alto Neuroscience Inc Company Information

ANRO Lician Score

ANRO Financial Snowflake

Upcoming Events for ANRO